Tag: life sciences

1
Indirect Patent Infringement Down Under
2
Federal Circuit Further Clarifies Venue in Hatch-Waxman Cases
3
UAE to Join the Madrid Protocol
4
Finally – German Constitutional Court Clears the Way for the Unified Patent Court
5
A Welcome Proposal to Introduce a Grace Period Into the Australian Designs Act
6
Deep fakes, inventorship and ethics – WIPO revised issues paper on Artificial Intelligence
7
After the CJEU’s decision now there is a final High Court judgment in the Sky v SkyKick case
8
German Constitutional Court partly slows down the Unified Patent Court Agreement Process
9
More than financial – blockchain’s potential in the healthcare and life sciences industries
10
Producers of generic medicines and biosimilars even more supported by EU

Indirect Patent Infringement Down Under

The issue of contributory infringement of a patent under the Australian Patents Act 1990 (Act) does not often arise for consideration by the Australian judicial system. When it does arise, the question of whether or not the product supplied is a ‘staple commercial product’ under the relevant provisions of the Act is always of particular interest.

In only a few cases has the impugned product been held to be a staple commercial product, and so any case that expands upon that product class is a particularly valuable aid. It is therefore of interest that the Full Court of the Australian Federal Court has recently considered contributory infringement in Hood v Down Under Enterprises International Pty Limited [2022] FCAFC 69.

Read More

Federal Circuit Further Clarifies Venue in Hatch-Waxman Cases

Last year, in Valeant Pharmaceuticals North America LLC v. Mylan Pharmaceuticals Inc., the Federal Circuit confirmed that 28 U.S.C. § 1400(b) is the sole venue provision for domestic defendants in Hatch-Waxman actions.1 On Friday 5 November 2021, the Federal Circuit provided even greater clarity on venue rules in such cases, concluding that, for venue purposes, only submission of the ANDA qualifies as an act of infringement, not any action related to the submission.2

Read More

UAE to Join the Madrid Protocol

In great news for companies that file trade marks internationally, the Government of the United Arab Emirates has agreed to join the Madrid Protocol from 28 December 2021.

Read More

Finally – German Constitutional Court Clears the Way for the Unified Patent Court

Today the German Federal Constitutional Court rejected two applications for an interim injunction against the German implementation of the Unified Patent Court Agreement (UPCA). The outcome of the decisions is a clear yes to a European patent court system!

Read More

A Welcome Proposal to Introduce a Grace Period Into the Australian Designs Act

The Designs Amendment (Advisory Council on Intellectual Property Response) Bill 2020 (Bill), with important changes to designs law, is currently before Senate for consideration. It includes a much-anticipated change to implement a grace period that will allow designers to publish their designs before applying for design protection.

Read More

Deep fakes, inventorship and ethics – WIPO revised issues paper on Artificial Intelligence

One thing is clear about artificial intelligence (AI) and intellectual property (IP) at the moment: there are more questions than answers. Who should be author? Who is responsible for a work’s liability? What about moral rights? Is a computer programme capable of making an ‘inventive step’ or forming an ‘intellectual creation’ normally reserved for humans? And for those Matrix fans – should we let machines make decisions for us, lest we become seen as the planet’s true virus?

In September 2019, the World Intellectual Property Organisation (WIPO) launched a much-needed conversation on IP and AI, and consulted with member state representatives on the potential impact of AI on IP. Over the course of the consultation, WIPO received more than 250 responses from a wide range of global stakeholders.

Read More

After the CJEU’s decision now there is a final High Court judgment in the Sky v SkyKick case

After the CJEU’s ruling earlier this year (as discussed here), the Sky v Skykick case has now returned to the English High Court and Lord Justice Arnold on 29 April 2020 issued a final judgment in the case (see full text of the judgment here).

Although Sky’s trade marks were found to be partially invalid on the ground that they were applied for in bad faith, Sky was still ultimately successful in establishing infringement.

Read More

German Constitutional Court partly slows down the Unified Patent Court Agreement Process

Today the German Federal Constitutional Court announced its decision in the complaint against the German implementation of the Unified Patent Court Agreement (UPCA). The outcome of the decision is a clear yes-and-no!

Read More

More than financial – blockchain’s potential in the healthcare and life sciences industries

Blockchain technology is considered by many to be one of the most important technologies developed in recent years. It is often misunderstood and its potential has yet to be fully realised and harnessed. Blockchain has been the subject of a large amount of negative press due to volatile price fluctuations of its biggest user, the cryptocurrency, and this has generated a public mistrust.

However, blockchain could hold the answer to two of technology’s greatest challenges: data reliability and security. These two things are particularly important in the healthcare and life sciences sector where veracity of data is a life or death question and the safety of our most intimate data is paramount.

Read More

Producers of generic medicines and biosimilars even more supported by EU

Effective 1 July 2019, the EU adopted a regulation by introducing a supplementary protection certificate (SPC) manufacturing and stockpiling waiver. This waiver also applies for biosimilar versions of SPC-protected medicine during the term of the SPC.

Read More

Copyright © 2022, K&L Gates LLP. All Rights Reserved.